Yong Xiao

Yong Xiao

Auto-generated profile, based on publicly available information

Yong Xiao

Nanjing Medical University

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 February 2023 in Science Advances
Verified
Journal Article
Closed access
YWYazhe Wang
Yazhe Wang
SMShipra Malik
Shipra Malik
HSHee-Won Suh
Hee-Won Suh
YXYong Xiao
Yong Xiao
YDYanxiang Deng
Yanxiang Deng
RBRaman Bahal
Raman Bahal
Glioblastoma (GBM) is one of the most lethal malignancies with poor survival and high recurrence rates. Here, we aimed to simultaneously target oncomiRs 10b and 21, reported to drive GBM progression and invasiveness. We designed short (8-mer) γ-modified peptide nucleic acids (sγPNAs), targeting the seed region of oncomiRs 10b and 21. We entrapped these anti-miR sγPNAs in nanoparticles (NPs) formed from a block copolymer of poly(lactic acid) and hyperbranched polyglycerol (PLA-HPG). The surface of the NPs was functionalized with aldehydes to produce bioadhesive NPs (BNPs) with superior transfection efficiency and tropism for tumor cells. When combined with temozolomide, sγPNA BNPs administered via convection-enhanced delivery (CED) markedly increased the survival (>120 days) of two orthotopic (intracranial) mouse models of GBM. Hence, we established that BNPs loaded with anti-seed sγPNAs targeting multiple oncomiRs are a promising approach to improve the treatment of GBM, with a potential to personalize treatment based on tumor-specific oncomiRs.

25 January 2023 in Cancer Research
Verified
Journal Article
Closed access
PDF file
MZMengjie Zhao
Mengjie Zhao
YLYanhui Li
Yanhui Li
CLChenfei Lu
Chenfei Lu
FDFangshu Ding
Fangshu Ding
MXMiao Xu
Miao Xu
XQXu Qian
Xu Qian
Radiotherapy is a major component of standard-of-care treatment for gliomas, the most prevalent type of brain tumor. However, resistance to radiotherapy remains a major concern. Identification of mechanisms governing radioresistance in gliomas could reveal improved therapeutic strategies for treating patients. Here, we report that mitochondrial metabolic pathways are suppressed in radioresistant gliomas through integrated analyses of transcriptomic data from glioma specimens and cell lines. Decreased expression of peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC1α), the key regulator of mitochondrial biogenesis and metabolism, correlated with glioma recurrence and predicted poor prognosis and response to radiotherapy of patients with glioma. The subpopulation of glioma cells with low-mitochondrial-mass exhibited reduced expression of PGC1α and enhanced resistance to radiotherapy treatment. Mechanistically, PGC1α was phosphorylated at serine (S) 636 by DNA-dependent protein kinase in response to irradiation. Phosphorylation at S636 promoted the degradation of PGC1α by facilitating its binding to the E3 ligase RNF34. Restoring PGC1α activity with expression of PGC1α S636A, a phosphorylation-resistant mutant, or a small-molecule PGC1α activator ZLN005 increased radiosensitivity of resistant glioma cells by reactivating mitochondria-related reactive oxygen species production and inducing apoptotic effects both in vitro and in vivo. In summary, this study identified a self-protective mechanism in glioma cells in which radiotherapy-induced degradation of PGC1α and suppression of mitochondrial biogenesis play a central role. Targeted activation of PGC1α could help improve response to radiotherapy in patients with glioma. Significance: Glioma cells reduce mitochondrial biogenesis by promoting PGC1α degradation to promote resistance to radiotherapy, indicating potential therapeutic strategies to enhance radiosensitivity.

21 December 2024 in Heliyon
Verified
Journal Article
Open access
YXYong Xiao
Yong Xiao
MZMengjie Zhao
Mengjie Zhao
RWRan Wang
Ran Wang
LLLiang Liu
Liang Liu
CXChong Xiang
Chong Xiang
KYKun Yang
Kun Yang
Emerging perspectives on tumor metabolism reveal its heterogeneity, a characteristic yet to be fully explored in gliomas. To advance therapies targeting metabolic processes, it is crucial to uncover metabolic differences and identify distinct metabolic subtypes. Therefore, we aimed to develop a classification system for gliomas based on the enrichment levels of four key metabolic pathways: glutaminolysis, glycolysis, the pentose phosphate pathway, and fatty acid oxidation. Energy-related features of glioma were characterized through integrative analyses of multiple datasets, including bulk, single-cell, and spatial transcriptome profiling. The glioma energy metabolic subtypes were constructed using the R package ConsensusClusterPlus. Kaplan-Meier analysis was conducted to compare clinical outcomes between different metabolic groups. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were employed to elucidate the biological functions of genes of interest. Cell-cell communication analysis was performed at single-cell resolution using the R package CellChat and at spatial resolution using the standard stLearn pipeline. Glioma samples were stratified into two prognostic subtypes. Group 1, enriched in the glutaminolysis pathway, had better clinical outcomes. In contrast, Group 2 exhibited high activities in glycolysis, the pentose phosphate pathway, and fatty acid oxidation, correlating with decreased survival time. Group 1 samples were predominantly located in the peripheral region and had a high composition of neuron cells. Group 2, however, had increased infiltration of tumor-promoting immune cells, such as M2 macrophages, and was characterized by traits of invasion, hypoxia, and immunity. Lastly, cell-cell communications were compared across different tumor regions, and the CX3CL1/CX3CR1 ligand-receptor pair was validated using spatial transcriptomic data. Our work revealed the metabolic heterogeneity in glioma by developing a new classification system with significant prognostic and therapeutic value. Single-cell transcriptional profiles offer novel insights into tumor metabolic reprogramming, which could enhance therapies tailored to cell- or patient-specific metabolic patterns.

1 August 2021 in Pathology - Research and Practice
Verified
Journal Article
Closed access
WJWei Ji
Wei Ji
JJJiantong Jiao
Jiantong Jiao
CCChao Cheng
Chao Cheng
YXYong Xiao
Yong Xiao
JSJunfei Shao
Junfei Shao
HLHongyi Liu
Hongyi Liu

26 April 2026 in Neurological Research
Verified
Journal Article
Closed access
YXYong Xiao
Yong Xiao
CXChenguang Xu
Chenguang Xu
PLPan Li
Pan Li
YLYong Liu
Yong Liu
LGLiangyuan Geng
Liangyuan Geng
CXChong Xiang
Chong Xiang
Venous compression is an underrecognized cause of trigeminal neuralgia (TN) and remains controversial due to its subtle imaging manifestations, variable anatomy, and uncertain optimal surgical management. This study aimed to clarify the anatomical spectrum of venous offenders, evaluate surgical outcomes, and explore the role of adjunctive trigeminal nerve combing (NC) in selected cases. We retrospectively analyzed 31 patients with primary TN who underwent microvascular decompression (MVD) between 2017 and 2023 and were confirmed intraoperatively to have pure venous compression (n = 11) or mixed arteriovenous compression (n = 20). Preoperative evaluation, operative videos, complications, and follow-up status were reviewed. Follow-up averaged 5 years. Pure venous compression was frequently associated with mild indentation-type conflict and markedly thickened arachnoid membranes, whereas mixed compression more commonly caused trigeminal root entry zone (REZ) distortion. The transverse pontine vein was the predominant offender. At discharge, pain-free status (BNI I) was achieved in 82% of pure venous and 95% of mixed cases. Long-term pain-free rates were 72% of pure venous and 80% of mixed patients. Recurrence occurred in 18% of pure venous and 10% of mixed cases (p > 0.05). Five patients with low-tension pure venous compression underwent adjunctive NC, achieving satisfactory long-term relief. Complications were mild and transient; no venous infarction occurred. Venous compression constitutes a distinct and surgically manageable subtype of TN. When combined with full-length exposure from the REZ to Meckel's cave, tailored approaches - including selective venous transposition or division and NC for low-tension adhesions - achieve durable pain control with minimal morbidity.

2 June 2025 in Journal of Craniofacial Surgery
Verified
Journal Article
Closed access
YXYong Xiao
Yong Xiao
PLPan Mmed Li
Pan Mmed Li
LLLiang Liu
Liang Liu
WSWenxiong Mmed Song
Wenxiong Mmed Song
RWRan Wang
Ran Wang
YZYuanjie Zou
Yuanjie Zou
Objective: This study aimed to analyze the anatomic variations of the trigeminal arachnoid membrane (TM) and evaluate its implications for microvascular decompression (MVD) surgery in patients with trigeminal neuralgia (TN). Understanding the structural variations of TM is essential for improving surgical outcomes. Methods: A retrospective analysis was conducted on 377 TN patients who underwent MVD between January 2017 and December 2023. Intraoperative video recordings were reviewed to classify the TM into 4 subtypes based on consistency, opacity, and thickness. Patients were followed for at least 10 months, with surgical techniques, including trigeminal nerve isolation, utilized to manage neurovascular conflicts and arachnoid adhesions. Results: The TM was classified into 4 subtypes: absent (10.3%), filamentous (41.1%), membranous (43.5%), and thickened (5.1%). Neurovascular conflicts were present in 97.3% of cases, with the superior cerebellar artery being the most common offending vessel. TM subtypes influenced the complexity of the surgery, with thicker and more opaque TMs presenting challenges in visualization and nerve decompression. Conclusions: The anatomic variations of TM play a critical role in MVD for TN. Understanding these subtypes enables more precise surgical planning, potentially reducing complications and recurrence. Standardized protocols for managing arachnoid membranes could improve outcomes and reduce the recurrence of TN symptoms. Future research should focus on developing advanced surgical tools and techniques to address the challenges posed by TM, particularly the thickened subtype.